

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 May 2026

### The effect of local fibrinogen administration on postoperative bleeding in CABG patients

#### Protocol summary

##### Summary

This randomized clinical trial assessed the effect of local fibrinogen on the amount of postoperative bleeding and the need for blood transfusion in adult patients undergoing CABG to compare the results with local placebo

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201510222804N9**

Registration date: **2015-12-08, 1394/09/17**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2015-12-08, 1394/09/17

##### Registrant information

###### Name

Ali Dabbagh

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 21 2243 2572

###### Email address

alidabbagh@sbmu.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

Shahid Beheshti University of Medical Sciences

##### Expected recruitment start date

2015-09-30, 1394/07/08

##### Expected recruitment end date

2016-02-29, 1394/12/10

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of local fibrinogen administration on postoperative bleeding in CABG patients

##### Public title

The effect of local fibrinogen administration on postoperative bleeding in CABG patients

##### Purpose

Prevention

##### Inclusion/Exclusion criteria

Inclusion criteria: age between 40-75 years old; elective CABG with CPB; constant surgeon; informed written consent. The following conditions were considered as exclusion criteria: emergent or urgent surgery; age more than 75 years or less than 40 years old; diabetes mellitus (or any of its complications like diabetic ketoacidosis or non-ketonic hyperosmolar diabetic coma); any previous history of stroke or underlying cerebral vascular disease; history of deep vein thrombosis; history of underlying hematologic disorders; any carotid plaque creating significant stenosis (stenosis > 75%); underlying pulmonary disorders affecting the spirometry indices significantly (>50% decrease); acute renal failure; chronic kidney disease causing serum Cr>2mg/dL; hepatic failure causing liver function test failure (> 3 times than normal); off pump CABG; any unwanted complication in the operation period; re-starting CPB after weaning from bypass; pulmonary artery pressure >30 before operation; ejection fraction<30%; congestive heart failure.

##### Age

From **40 years** old to **75 years** old

##### Gender

Both

## Phase

3

## Groups that have been masked

No information

## Sample size

Target sample size: 50

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Double blinded

## Blinding description

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Shahid Beheshti University of Medical Sciences

##### Street address

Velenjak; Chamran Exp Way; Tehran; Iran

##### City

Tehran

##### Postal code

1417613151

#### Approval date

2011-06-02, 1390/03/12

#### Ethics committee reference number

1567

## Health conditions studied

### 1

#### Description of health condition studied

coronary artery bypass graft

#### ICD-10 code

I25.1

#### ICD-10 code description

Atherosclerotic heart disease

## Primary outcomes

### 1

#### Description

Postoperative bleeding

#### Timepoint

Early 24 hours in postoperative period

#### Method of measurement

Postoperative amount of blood loss in chest tube bottles

## Secondary outcomes

### 1

#### Description

Hematocrit level

#### Timepoint

Early 24 hours hematocrit in postoperative period

#### Method of measurement

Preoperative and postoperative hematocrit level

## Intervention groups

### 1

#### Description

After weaning from cardiopulmonary bypass and infusion of protamine, "fibrinogen" solution including 1 g of fibrinogen in 50 mL volume is flushed over the heart. Afterwards, sternum is closed and wired with steel wires. The surgeon is blind to the content of the 50 mL syringes; whether fibrinogen or placebo.

#### Category

Treatment - Drugs

### 2

#### Description

In the control (placebo) group, after weaning from bypass circuit and protamine infusion, 50 mL of distilled water is flushed over the heart, exactly the same method as fibrinogen. Finally afterwards, sternum is closed and wired with steel wires. The surgeon is blind to the content of the 50 mL syringes; whether fibrinogen or placebo.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Shahid Modarres Hospital

##### Full name of responsible person

Ali Dabbagh

##### Street address

Modarres Hospital, Saadat Abad

##### City

Tehran

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Vice chancellor for research, Shahid Beheshti

University of Medical Sciences

**Full name of responsible person**

Dr Afshin Zarghi

**Street address**

Shahid Beheshti University of Medical Sciences,  
Velenjak, Chamran Exp Way

**City**

Tehran

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for research, Shahid Beheshti University  
of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Anesthesiology Research Center

**Full name of responsible person**

Ali Dabbagh

**Position**

MD, Professor

**Other areas of specialty/work**

**Street address**

Cardiac Anesthesiology Dept. Modarres Hospital,  
Saadat Abad

**City**

Tehran

**Postal code**

1417613151

**Phone**

+98 21 2243 2572

**Fax**

**Email**

alidabbagh@yahoo.com; alidabbagh@sbm.ac.ir

**Web page address**

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Anesthesiology Research Center

**Full name of responsible person**

Ali Dabbagh

**Position**

MD, Professor of Cardiac Anesthesiology

**Other areas of specialty/work**

**Street address**

Anesthesiology Research Center, Velenjak, Tehran,  
Iran

**City**

Tehran

**Postal code**

1417613151

**Phone**

+98 21 2243 2572

**Fax**

+98 21 2243 2572

**Email**

alidabbagh@yahoo.com; alidabbagh@sbm.ac.ir

**Web page address**

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Anesthesiology Research Center

**Full name of responsible person**

Ali Dabbagh

**Position**

MD, Professor of Cardiac Anesthesiology

**Other areas of specialty/work**

**Street address**

Modarres Hospital, Saadat Abad

**City**

Tehran

**Postal code**

1417613151

**Phone**

+98 21 2243 2572

**Fax**

**Email**

alidabbagh@yahoo.com

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*